Relmada Therapeutics (RLMD) News Today $0.35 -0.01 (-1.41%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$0.35 +0.00 (+0.29%) As of 01/31/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Short Interest in Relmada Therapeutics, Inc. (NASDAQ:RLMD) Drops By 24.2%January 31 at 3:45 AM | americanbankingnews.comRelmada Therapeutics faces potential Nasdaq delistingJanuary 27, 2025 | msn.comRelmada To Discontinue REL-1017 Reliance II And Relight Phase 3 Trials; Mulls SaleDecember 10, 2024 | markets.businessinsider.comRelmada Therapeutics Shifts Focus After Study DiscontinuationDecember 10, 2024 | markets.businessinsider.comRelmada seeking strategic options after failed studyDecember 10, 2024 | seekingalpha.comRelmada seeking strategic options, stock climbs 5%December 10, 2024 | msn.comRelmada discontinues late-stage trials for depression drug, explores saleDecember 9, 2024 | reuters.comRelmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017December 9, 2024 | globenewswire.comMizuho Downgrades Relmada Therapeutics (RLMD)December 6, 2024 | msn.comMizuho Securities downgrades Relmada Therapeutics (RLMD) to a HoldDecember 5, 2024 | markets.businessinsider.comLeerink Partners Downgrades Relmada Therapeutics (RLMD)December 5, 2024 | msn.comRelmada reports DMC assessment indicates Phase 3 Reliance II trial is futileDecember 5, 2024 | finance.yahoo.comRelmada Therapeutics Stock Plummets Losing 80% Value - Here's WhyDecember 4, 2024 | benzinga.comRelmada Study of Major-Depression Treatment Deemed Futile; Shares Plummet - UpdateDecember 4, 2024 | marketwatch.comRelmada Therapeutics Study of Major Depressive Disorder Treatment Assessed as FutileDecember 4, 2024 | marketwatch.comRelmada's depression drug unlikely to meet main trial goal, analysis showsDecember 4, 2024 | reuters.comRelmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical SignificanceDecember 4, 2024 | globenewswire.comVestal Point Capital LP Has $1.59 Million Stake in Relmada Therapeutics, Inc. (NASDAQ:RLMD)Vestal Point Capital LP lowered its holdings in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD - Free Report) by 59.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 490,000 shares of the comNovember 29, 2024 | marketbeat.comRelmada Therapeutics (NASDAQ:RLMD) Stock Price Down 1.4% - Here's What HappenedRelmada Therapeutics (NASDAQ:RLMD) Trading Down 1.4% - Time to Sell?November 27, 2024 | marketbeat.comKuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law FirmNovember 21, 2024 | globenewswire.comRelmada Therapeutics to Present at Jefferies London Healthcare ConferenceNovember 20, 2024 | markets.businessinsider.comRelmada Therapeutics initiates Phase 1 dosing with REL-P11November 14, 2024 | markets.businessinsider.comRelmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic DiseaseNovember 14, 2024 | globenewswire.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2024 Earnings Call TranscriptNovember 11, 2024 | msn.comRelmada Therapeutics: Strong Buy on Promising Pipeline and Financial StabilityNovember 11, 2024 | markets.businessinsider.comRelmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call TranscriptNovember 10, 2024 | seekingalpha.comRelmada Therapeutics Inc. Reports Q3 2024 Financial ResultsNovember 8, 2024 | markets.businessinsider.comRelmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 7, 2024 | prnewswire.comRelmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 7, 2024 | globenewswire.comA Look Ahead: Relmada Therapeutics's Earnings ForecastNovember 6, 2024 | benzinga.comRelmada Therapeutics (RLMD) to Release Quarterly Earnings on ThursdayRelmada Therapeutics (NASDAQ:RLMD) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.November 5, 2024 | marketbeat.comRelmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024November 4, 2024 | globenewswire.comQ3 Earnings Estimate for RLMD Issued By Leerink PartnrsRelmada Therapeutics, Inc. (NASDAQ:RLMD - Free Report) - Analysts at Leerink Partnrs dropped their Q3 2024 earnings estimates for Relmada Therapeutics in a research report issued on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings per sOctober 18, 2024 | marketbeat.comRelmada Therapeutics (NASDAQ:RLMD) Stock Quotes, Forecast and News SummaryOctober 14, 2024 | benzinga.comHow To Find The Insider Trades That Consistently Outperform The Market – Under The RadarOctober 10, 2024 | benzinga.comRelmada Therapeutics (NASDAQ:RLMD) Shares Down 0.3% - What's Next?Relmada Therapeutics (NASDAQ:RLMD) Stock Price Down 0.3% - Here's WhyOctober 9, 2024 | marketbeat.comJefferies Upgrades Relmada Therapeutics (RLMD)September 18, 2024 | msn.comRelmada jumps as Jefferies upgrades on a potential turnaround storySeptember 18, 2024 | msn.comKuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law FirmSeptember 16, 2024 | prnewswire.comRelmada therapeutics CEO acquires shares worth over $395kSeptember 13, 2024 | uk.investing.comRelmada Therapeutics director buys $33,280 in company stockSeptember 13, 2024 | uk.investing.comInsider Spends US$395k Buying More Shares In Relmada TherapeuticsSeptember 13, 2024 | sg.finance.yahoo.comInsider Buying: Relmada Therapeutics, Inc. (NASDAQ:RLMD) CFO Acquires 8,194 Shares of StockSeptember 12, 2024 | insidertrades.comInsider Buying: CFO Maged Shenouda Acquires Shares of Relmada Therapeutics Inc (RLMD)September 12, 2024 | finance.yahoo.comRelmada Therapeutics Inc (RLMD) CEO Sergio Traversa Acquires 140,000 SharesSeptember 12, 2024 | finance.yahoo.comInsider Buying: Relmada Therapeutics, Inc. (NASDAQ:RLMD) CFO Buys 8,194 Shares of StockRelmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) CFO Maged Shenouda purchased 8,194 shares of the stock in a transaction dated Monday, September 9th. The stock was acquired at an average cost of $2.55 per share, for a total transaction of $20,894.70. Following the transaction, the chief financial officer now owns 43,097 shares of the company's stock, valued at $109,897.35. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.September 11, 2024 | marketbeat.comRelmada Therapeutics (NASDAQ:RLMD) Trading 16.3% Higher Relmada Therapeutics (NASDAQ:RLMD) Shares Up 16.3%September 10, 2024 | marketbeat.comKuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law FirmSeptember 5, 2024 | globenewswire.comRLMD Sep 2024 5.000 put (RLMD240920P00005000)August 19, 2024 | finance.yahoo.comLeerink Partnrs Equities Analysts Lift Earnings Estimates for Relmada Therapeutics, Inc. (NASDAQ:RLMD)Relmada Therapeutics, Inc. (NASDAQ:RLMD - Free Report) - Stock analysts at Leerink Partnrs increased their Q3 2024 EPS estimates for Relmada Therapeutics in a note issued to investors on Wednesday, August 7th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings peAugust 12, 2024 | marketbeat.com Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address RLMD Media Mentions By Week RLMD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RLMD News Sentiment▼0.960.69▲Average Medical News Sentiment RLMD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RLMD Articles This Week▼41▲RLMD Articles Average Week Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Atara Biotherapeutics News Iterum Therapeutics News Anebulo Pharmaceuticals News RAPT Therapeutics News VYNE Therapeutics News Tempest Therapeutics News Barinthus Biotherapeutics News Actinium Pharmaceuticals News CASI Pharmaceuticals News Q32 Bio News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RLMD) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
